DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
97	潰瘍性大腸炎	2

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000037261	2020-10-01	2020-08-27	Study on the clinic of stasis removing and renewal therapy for ulcerative colitis based on serum exosome miRNA to regulate the immune microenvironment	Study on the clinic of stasis removing and renewal therapy for ulcerative colitis based on serum exosome miRNA to regulate the immune microenvironment	Ulcerative Colitis	experimental group:stasis removing and immunoregulation therapy;control group:mesalamine;	Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai	NULL	Recruiting	18	65	Both	experimental group:30;control group:30;		China
2	ChiCTR2000028869	2020-01-03	2020-01-05	phase IIa clinical trial of Colitis Suppositories	A multicenter, randomized, blinded management, positive-drug parallel-controlled, preliminary exploratory phase IIa clinical trial on the efficacy and safety of Colitis Suppositories in the treatment for mild-to-moderate active ulcerative colitis (Qi-Deficiency and Blood-Stasis Syndrome), compared with the Mesalazine Suppositories (Salofalk)	mild-to-moderate active ulcerative colitis (Qi-Deficiency and Blood-Stasis Syndrome)	Experimental group:Colitis Suppositories, one at a time, twice a day, in the early and late anal plug into the rectum.;The control group:Mesalazine Suppositories, one at a time, twice a day, in the early and late anal plug into the rectum.;	Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University	NULL	Recruiting	18	65	Both	Experimental group:30;The control group:30;	Phase 2	China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

ChiCTR2000037261

2020-10-01

2020-08-27

Study on the clinic of stasis removing and renewal therapy for ulcerative colitis based on serum exosome miRNA to regulate the immune microenvironment

Ulcerative Colitis

experimental group:stasis removing and immunoregulation therapy;control group:mesalamine;

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai

NULL

Recruiting

Both

experimental group:30;control group:30;

China

ChiCTR2000028869

2020-01-03

2020-01-05

phase IIa clinical trial of Colitis Suppositories

A multicenter, randomized, blinded management, positive-drug parallel-controlled, preliminary exploratory phase IIa clinical trial on the efficacy and safety of Colitis Suppositories in the treatment for mild-to-moderate active ulcerative colitis (Qi-Deficiency and Blood-Stasis Syndrome), compared with the Mesalazine Suppositories (Salofalk)

mild-to-moderate active ulcerative colitis (Qi-Deficiency and Blood-Stasis Syndrome)

Experimental group:Colitis Suppositories, one at a time, twice a day, in the early and late anal plug into the rectum.;The control group:Mesalazine Suppositories, one at a time, twice a day, in the early and late anal plug into the rectum.;

Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University

NULL

Recruiting

Both

Experimental group:30;The control group:30;

Phase 2

China